VictorMoyoMD
Oncology • Farmington, CTSpecialist in hematology & oncology, currently treats patients in Farmington, Connecticut.
Dr. Moyo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
263 Farmington Ave
Farmington, CT 06030Phone+1 860-679-2100Fax+1 860-679-4815
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2002- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2000
George Washington UniversityResidency, Internal Medicine, 1996 - 1999
University of Zimbabwe Huggins SOMClass of 1991
Certifications & Licensure
PA State Medical License 2008 - 2014
Clinical Trials
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer Start of enrollment: 2010 Jun 01
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- 15 citationsPhase 1 Dose Escalation Study of Seribantumab (MM-121), an anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid TumorsCrystal S. Denlinger, Vicki L. Keedy, Victor Moyo, Gavin MacBeath, Geoffrey I. Shapiro
Investigational New Drugs. 2021-07-11 - 9 citationsLiposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.Paul-Michel Mertes, Olivier Collange, Pierre Coliat, Mainak Banerjee, Marie-Charlotte Diringer
Journal of Controlled Release. 2021-06-24 - 62 citationsSafety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-...Pamela N. Munster, Ian E. Krop, Patricia LoRusso, Cynthia X. Ma, Barry A. Siegel
British Journal of Cancer. 2018-10-26
Press Mentions
L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401, Featured at the 2020 Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO)June 10th, 2020
L.E.A.F. Pharmaceuticals Receives Positive US FDA Feedback and Comprehensive Roadmap for Clinical Development as Well as Registration of Its Four Lead Novel Anticancer DrugsOctober 30th, 2018
Grant Support
- Antigenics Renal CarcinomaNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
